HuGE Literature Finder
Records
1
-
30
| A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01). Thoracic cancer 2022 Jun 13 (12): 1827-1836. Asami Kazuhiro, Ando Masahiko, Nishimura Takashi, Yokoi Takashi, Tamura Atsuhisa, Minato Koichi, Mori Masahide, Ogushi Fumitaka, Yamamoto Akiyoshi, Yoshioka Hiroshige, Kawahara Masaaki, Atagi Shin |
| Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. European journal of cancer (Oxford, England : 1990) 2022 May 170 64-72. Rossini Daniele, Germani Marco M, Lonardi Sara, Pietrantonio Filippo, Dell'Aquila Emanuela, Borelli Beatrice, Allegrini Giacomo, Maddalena Giulia, Randon Giovanni, Marmorino Federica, Zaniboni Alberto, Buonadonna Angela, Boccaccino Alessandra, Conca Veronica, Antoniotti Carlotta, Passardi Alessandro, Masi Gianluca, Cremolini Chia |
| Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. BMC medicine 2022 Feb 20 (1): 42. Song Zhengbo, Li Yuping, Chen Shiqing, Ying Shenpeng, Xu Shuguang, Huang Jianjin, Wu Dan, Lv Dongqing, Bei Ting, Liu Shuxun, Huang Xiaoping, Xie Congying, Wu Xiaoyu, Fu Jianfei, Hua Feng, Wang Wenxian, Xu Chunwei, Gao Chan, Cai Shangli, Lu Shun, Zhang Yipi |
| Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 Feb . Shi Yuankai, Zhao Yanqiu, Yang Sheng, Zhou Jianying, Zhang Liangming, Chen Gongyan, Fang Jian, Zhu Bo, Li Xingya, Shu Yongqian, Shi Jianhua, Zheng Rongsheng, Wang Donglin, Yu Huiqing, Huang Jianan, Zhuang Zhixiang, Wu Gang, Zhang Longzhen, Guo Zhongliang, Greco Michael, Li Xiao, Zhang |
| Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). European journal of cancer (Oxford, England : 1990) 2021 Nov 159 144-153. Sakata Yoshihiko, Sakata Shinya, Oya Yuko, Tamiya Motohiro, Suzuki Hidekazu, Shibaki Ryota, Okada Asuka, Kobe Hiroshi, Matsumoto Hirotaka, Yokoi Takashi, Sato Yuki, Uenami Takeshi, Saito Go, Tsukita Yoko, Inaba Megumi, Ikeda Hideki, Arai Daisuke, Maruyama Hirotaka, Hara Satoshi, Tsumura Shinsuke, Morinaga Jun, Sakagami Taku |
| Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). International journal of clinical oncology 2021 Oct . Tsubata Yukari, Watanabe Kana, Saito Ryota, Nakamura Atsushi, Yoshioka Hiroshige, Morita Mami, Honda Ryoichi, Kanaji Nobuhiro, Ohizumi Satoshi, Jingu Daisuke, Nakagawa Taku, Nakazawa Kensuke, Mouri Atsuto, Takeuchi Susumu, Furuya Naoki, Akazawa Yuki, Miura Kiyotaka, Ichihara Eiki, Maemondo Makoto, Morita Satoshi, Kobayashi Kunihiko, Isobe Takes |
| Lung cancer epidermal growth factor receptor mutations and radiotherapy response: A multicentre clinical study. Clinical and translational radiation oncology 2021 Sep 30 15-18. Hsu Fred, Sit Daegan, Pastuch Andrea, Dingler Angie, Atwal Parmve |
| Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA oncology 2021 Aug . Martinelli Erika, Martini Giulia, Famiglietti Vincenzo, Troiani Teresa, Napolitano Stefania, Pietrantonio Filippo, Ciardiello Davide, Terminiello Marinella, Borrelli Carola, Vitiello Pietro Paolo, De Braud Filippo, Morano Federica, Avallone Antonio, Normanno Nicola, Nappi Anna, Maiello Evaristo, Latiano Tiziana, Falcone Alfredo, Cremolini Chiara, Rossini Daniele, Santabarbara Giuseppe, Pinto Carmine, Santini Daniele, Cardone Claudia, Zanaletti Nicoletta, Di Liello Alessandra, Renato Daniela, Esposito Lucia, Marrone Francesca, Ciardiello Fortuna |
| Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases. Investigational new drugs 2021 Jul . Kaneda Hiroyasu, Sawa Kenji, Daga Haruko, Okada Asuka, Nakatani Yuki, Atagi Shinji, Okishio Kyoichi, Tani Yoko, Matsumoto Yoshiya, Ogawa Koichi, Nakahama Kenji, Izumi Motohiro, Mitsuoka Shigeki, Kawaguchi Tomo |
| Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical colorectal cancer 2021 Jul . Alshammari Kanan, Aung Kyaw L, Zhang Tong, Razak Albiruni R A, Serra Stefano, Stockley Tracy, Wang Lisa, Nguyen Jessica, Spreafico Anna, Hansen Aaron R, Zwir Dave, Siu Lillian L, Bedard Philippe |
| Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs. Cancer biomarkers : section A of Disease markers 2021 May . Arrieta Oscar, Hernández-Martínez Juan-Manuel, Montes-Servín Edgar, Heredia David, Cardona Andrés F, Molina-Romero Camilo, Lara-Mejía Luis, Diaz-Garcia Diego, Bahena-Gonzalez Antonio, Mendoza-Oliva Dolores |
| NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Molecular oncology 2021 May . Sánchez-Herrero Estela, Serna-Blasco Roberto, Ivanchuk Vadym, García-Campelo Rosario, Dómine Gómez Manuel, Miguel Sánchez José, Massutí Bartomeu, Reguart Noemi, Camps Carlos, Sanz-Moreno Sandra, Calabuig-Fariñas Silvia, Jantus-Lewintre Eloísa, Arnal Magdalena, Fernández-Orth Dietmar, Calvo Virginia, González-Rumayor Víctor, Provencio Mariano, Romero Atoc |
| Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Targeted oncology 2021 Feb . Cheng Ying, He Yong, Li Wei, Zhang He-Long, Zhou Qing, Wang Buhai, Liu Chunling, Walding Andrew, Saggese Matilde, Huang Xiangning, Fan Minhao, Wang Jia, Ramalingam Suresh |
| PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. Clinical lung cancer 2021 Feb . Ferrara Miriam Grazia, Martini Maurizio, D'Argento Ettore, Forcella Chiara, Vita Emanuele, Di Noia Vincenzo, Sperduti Isabella, Bilotta Mirna, Ribelli Marta, Damiano Paola, Cannella Antonella, Stefani Alessio, Pilotto Sara, Carbone Carmine, Piro Geny, Milella Michele, Tortora Giampaolo, Bria Emil |
| Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. BioMed research international 2021 8850256. Ma Jie-Tao, Guo Yi-Jia, Song Jun, Sun Li, Zhang Shu-Ling, Huang Le-Tian, Jing Wei, Zhao Jian-Zhu, Han Cheng- |
| Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors. Cancer chemotherapy and pharmacology 2021 Jan . Verheijen R B, van Duijl T T, van den Heuvel M M, Vessies D, Muller M, Beijnen J H, Janssen J M, Schellens J H M, Steeghs N, van den Broek D, Huitema A D |
| Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study. Cancer management and research 2021 13 2033-2039. Peng Da, Shan Dongfeng, Dai Chengcheng, Li Jie, Wang Zifan, Huang Ziyi, Peng Rui, Zhao Peng, Ma Xuezh |
| First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer. Thoracic cancer 2020 Dec . Su Po-Lan, Chen Chian-Wei, Wu Yi-Lin, Lin Chien-Chung, Su Wu-Ch |
| MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway. Clinical colorectal cancer 2020 Dec . Chuang Jeremy, Wang Chongkai, Guo Yuming, Valenzuela Valerie, Wu Jun, Fakih Marw |
| Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Cureus 2020 Dec 12 (12): e12128. Pereira Isabel, Gaspar Cátia, Pina Marta, Azevedo Isabel, Rodrigues A |
| Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung cancer (Amsterdam, Netherlands) 2020 Nov 151 20-24. Yamamoto N, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Yamanaka T, Tanaka M, Takahashi K, Fukuoka |
| Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. EBioMedicine 2020 Nov 62 103103. Dietz Steffen, Christopoulos Petros, Yuan Zhao, Angeles Arlou Kristina, Gu Lisa, Volckmar Anna-Lena, Ogrodnik Simon J, Janke Florian, Fratte Chiara Dalle, Zemojtel Tomasz, Schneider Marc A, Kazdal Daniel, Endris Volker, Meister Michael, Muley Thomas, Cecchin Erika, Reck Martin, Schlesner Matthias, Thomas Michael, Stenzinger Albrecht, Sültmann Holg |
| EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patients. Thoracic cancer 2020 Sep . Leal Leticia F, Laus Ana C, Cavagna Rodrigo, de Paula Flavia E, de Oliveira Marco A, Ribeiro Dayana M, Hassan Fernanda M, Miziara José E, da Silva Eduardo C Albino, da Silva Vinicius D, De Marchi Pedro, Reis Rui |
| Erlotinib and bevacizumab in elderly patients =75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Investigational new drugs 2020 Aug . Aoshima Yoichiro, Karayama Masato, Inui Naoki, Yasui Hideki, Hozumi Hironao, Suzuki Yuzo, Furuhashi Kazuki, Fujisawa Tomoyuki, Enomoto Noriyuki, Nakamura Yutaro, Mikamo Masashi, Matsuura Shun, Kusagaya Hideki, Kaida Yusuke, Uto Tomohiro, Hashimoto Dai, Matsui Takashi, Asada Kazuhiro, Suda Takafu |
| Oncogene HSPH1 modulated by the rs2280059 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma. Carcinogenesis 2020 Aug . Li Yankang, Zhang Nasha, Zhang Li, Song Yemei, Liu Jie, Yu Jinming, Yang Mi |
| ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib. Translational lung cancer research 2020 Jun 9 (3): 532-540. Romero Atocha, Serna-Blasco Roberto, Alfaro Cristina, Sánchez-Herrero Estela, Barquín Miguel, Turpin María Carmen, Chico Sofía, Sanz-Moreno Sandra, Rodrigez-Festa Alejandro, Laza-Briviesca Raquel, Cruz-Bermudez Alberto, Calvo Virginia, Royuela Ana, Provencio Maria |
| Detection of Low-level EGFR c.2369 C?>?T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes. Pathology oncology research : POR 2020 Jun . Ye Linda, Mesbah Ardakani Nima, Thomas Carla, Spilsbury Katrina, Leslie Connull, Amanuel Benhur, Millward Micha |
| IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER. Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery 2020 33 (3): e1524. Zanatto Renato Morato, Santos Gianni, Oliveira Júnea Caris, Pracucho Eduardo Marcucci, Nunes Adauto José Ferreira, Lopes-Filho Gaspar Jesus, Saad Sarhan Sydn |
| Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. PloS one 2020 15 (12): e0244502. Chen Yu-Hung, Wang Tso-Fu, Chu Sung-Chao, Lin Chih-Bin, Wang Ling-Yi, Lue Kun-Han, Liu Shu-Hsin, Chan Sheng-Chi |
| Pleural Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer. In vivo (Athens, Greece) 0 34 (4): 2179-2185. Lim Jeong Uk, Yeo Chang Dong, Kim Hyung Woo, Kang Hye Seon, Park Chan Kwon, Kim Ju Sang, Kim Jin Woo, Kim Seung Joon, Lee Sang Ha |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: